Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
7 Biotech Stocks With Key Catalysts for May
06:35am, Wednesday, 11'th May 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo
FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease
07:54am, Thursday, 16'th Dec 2021
The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (molluscum), a common, highly contagio
Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?
12:17pm, Monday, 11'th Oct 2021
The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica Pharmaceuticals Inc. -VRCA
03:00am, Thursday, 23'rd Sep 2021
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA).
Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today
12:03pm, Tuesday, 21'st Sep 2021
The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.
Why Verrica Pharmaceuticals Shares Are Trading Lower Today
11:35am, Tuesday, 21'st Sep 2021
Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment o
VRCA Stock: Why It Significantly Decreased Today
11:20am, Tuesday, 21'st Sep 2021
The stock price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) fell by over 15% during intraday trading today. This is why it happened.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
10:49am, Tuesday, 21'st Sep 2021
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Verrica Pharma Shares Slide After Response Letter From FDA
07:58am, Tuesday, 21'st Sep 2021
The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly con
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
07:30am, Tuesday, 10'th Aug 2021
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
07:30am, Friday, 09'th Jul 2021
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
08:18pm, Saturday, 05'th Jun 2021
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such inv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
01:03am, Thursday, 03'rd Jun 2021
NEW YORK, June 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such investors a
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
09:46am, Monday, 31'st May 2021
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 –
